Comparative Pharmacology
Head-to-head clinical analysis: IBU TAB 200 versus ORUDIS KT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBU TAB 200 versus ORUDIS KT.
IBU-TAB 200 vs ORUDIS KT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for nonprescription use.
50 mg orally three times daily or 75 mg orally twice daily; maximum 300 mg/day.
None Documented
None Documented
2-4 hours (terminal half-life). Short half-life requires frequent dosing for sustained analgesic/antipyretic effect.
Terminal elimination half-life: 2-4 hours (increased in elderly and renal impairment, up to 12 hours).
Renal: 90% as metabolites (glucuronides, hydroxylated derivatives), <10% unchanged. Fecal: <5%.
Renal (approximately 60-80% as metabolites, <10% unchanged); biliary/fecal (approximately 20-35%).
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)